Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Clearside Biomedical Inc (CLSD): Cormorant Reveals 10.1% Stake

Page 1 of 10

Bihua Chen‘s Cormorant Asset Management has revealed a position in Clearside Biomedical Inc (NASDAQ:CLSD), through a 13G filing issued with the SEC yesterday. The filing, which has a June 1 Date of Event, shows that Cormorant Asset Management owns 1.99 million shares of the company, or 10.1% of its common stock. The Date of Event is one day before Clearside Biomedical Inc (NASDAQ:CLSD) went public on June 2, with an IPO offering of 7.20 million shares at $7.00 per share, suggesting that Cormorant was a private investor of the company before its IPO.

Clearside had originally planned to offer 4.00 million shares at between $14.00 and $16.00 per share, but met resistance. With the biotech sector enduring a lengthy downturn, drug makers have had difficulty generating interest in their offerings, which has led to Viamet Pharmaceuticals Holdings LLC and GenSight Biologics SA to recently cancel their intended IPOs. Shares of Clearside Biomedical Inc (NASDAQ:CLSD), which is working on first-in-class drug treatments targeting diseases that cause blindness, are down slightly since their IPO, currently trading at $6.90.

cell, stem, research, cold, liquid, nitrogen, medical, test, experiment, clothing, protective, artificial, white, temperature, laboratory, freeze, cryopreservation, samples,

Elena Pavlovich/Shutterstock.com

Cormorant Asset Management is the second investment firm tracked by Insider Monkey which has revealed a position in the company, following Rock Springs Capital revealing a 1.30-million share position in the stock last Friday, with a Date of Event of June 2, the day of the company’s IPO. The Kris Jenner, Gordon Bussard, and Graham McPhail-managed healthcare-investment firm has a 6.6% stake in the stock and was also invested in it while the company was private.

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Cormorant Global Healthcare Master Fund 0 1,658,151 0 1,658,151 1,658,151 8.5%
Cormorant Global Healthcare GP 0 1,658,151 0 1,658,151 1,658,151 8.5%
Cormorant Asset Management 0 1,988,208 0 1,988,208 1,988,208 10.1%
Bihua Chen 0 1,988,208 0 1,988,208 1,988,208 10.1%
Bihua Chen
Bihua Chen
Cormorant Asset Management

Page 1 of 10 – SEC Filing

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
OMB APPROVAL
OMB Number:3235-0145
Expires: February 28, 2009
Estimated average burden
hours per response… 10.4

 

SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. ___)*
Clearside Biomedical, Inc.
(Name of Issuer)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
15063104
(CUSIP Number)
June 1, 2016
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
[ ] Rule 13d-1(b)
[x] Rule 13d-1(c)
[ ] Rule 13d-1(d)
___________________________________
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
Follow Clearside Biomedical Inc.
Trade (CLSD) Now!
Page 1 of 10

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!